-
1
-
-
84855597543
-
Re-engineering biopharmaceuticals for targeted delivery across the blood-brain barrier
-
Pardridge, W. M. and Boado, R. J. (2012) Re-engineering biopharmaceuticals for targeted delivery across the blood-brain barrier Methods Enzymol. 503, 269-92
-
(2012)
Methods Enzymol.
, vol.503
, pp. 269-292
-
-
Pardridge, W.M.1
Boado, R.J.2
-
2
-
-
84860710411
-
Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy
-
Chirmule, N., Jawa, V., and Meibohm, B. (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy AAPS J. 14, 296-302
-
(2012)
AAPS J.
, vol.14
, pp. 296-302
-
-
Chirmule, N.1
Jawa, V.2
Meibohm, B.3
-
3
-
-
38449110954
-
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier
-
Boado, R. J., Zhang, Y., Xia, C. F., Wang, Y., and Pardridge, W. M. (2008) Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier Biotechnol. Bioeng. 99, 475-84
-
(2008)
Biotechnol. Bioeng.
, vol.99
, pp. 475-484
-
-
Boado, R.J.1
Zhang, Y.2
Xia, C.F.3
Wang, Y.4
Pardridge, W.M.5
-
4
-
-
69949114874
-
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery
-
Pardridge, W. M. and Boado, R. J. (2009) Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery Pharm. Res. 26, 227-36
-
(2009)
Pharm. Res.
, vol.26
, pp. 227-236
-
-
Pardridge, W.M.1
Boado, R.J.2
-
5
-
-
0025826050
-
Lysosomal storage diseases
-
Neufeld, E. F. (1991) Lysosomal storage diseases Annu. Rev. Biochem. 60, 257-80
-
(1991)
Annu. Rev. Biochem.
, vol.60
, pp. 257-280
-
-
Neufeld, E.F.1
-
6
-
-
0025938673
-
Human alpha-L-iduronidase: CDNA isolation and expression
-
Scott, H. S., Anson, D. S., Orsborn, A. M., Nelson, P. V., Clements, P. R., Morris, C. P., and Hopwood, J. J. (1991) Human alpha-L-iduronidase: cDNA isolation and expression Proc. Natl. Acad. Sci. U. S. A. 88, 9695-9
-
(1991)
Proc. Natl. Acad. Sci. U. S. A.
, vol.88
, pp. 9695-9699
-
-
Scott, H.S.1
Anson, D.S.2
Orsborn, A.M.3
Nelson, P.V.4
Clements, P.R.5
Morris, C.P.6
Hopwood, J.J.7
-
7
-
-
0035000479
-
Enzyme replacement therapy in mucopolysaccharidosis type I: Progress and emerging difficulties
-
Wraith, J. E. (2001) Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties J. Inherit. Metab. Dis. 24, 245-50
-
(2001)
J. Inherit. Metab. Dis.
, vol.24
, pp. 245-250
-
-
Wraith, J.E.1
-
8
-
-
16844384688
-
Enzyme replacement therapy in mucopolysaccharidosis type i
-
discussion 57.
-
Miebach., E. (2005) Enzyme replacement therapy in mucopolysaccharidosis type I Acta Paediatr. Suppl. 94, 58-60 discussion 57.
-
(2005)
Acta Paediatr.
, vol.94
, pp. 58-60
-
-
Miebach, E.1
-
9
-
-
79961050726
-
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein
-
Boado, R. J., Hui, E. K., Lu, J. Z., Zhou, Q. H., and Pardridge, W. M. (2011) Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein Mol. Pharm. 8, 1342-50
-
(2011)
Mol. Pharm.
, vol.8
, pp. 1342-1350
-
-
Boado, R.J.1
Hui, E.K.2
Lu, J.Z.3
Zhou, Q.H.4
Pardridge, W.M.5
-
10
-
-
70350236476
-
AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in rhesus monkeys
-
Boado, R. J., Hui, E. K., Lu, J. Z., and Pardridge, W. M. (2009) AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in rhesus monkeys J. Biotechnol. 144, 135-41
-
(2009)
J. Biotechnol.
, vol.144
, pp. 135-141
-
-
Boado, R.J.1
Hui, E.K.2
Lu, J.Z.3
Pardridge, W.M.4
-
11
-
-
0037260746
-
Evaluation of large-sized brains for neurotoxic endpoints
-
Garman, R. H. (2003) Evaluation of large-sized brains for neurotoxic endpoints Toxicol. Pathol. 31 (Suppl) 32-43
-
(2003)
Toxicol. Pathol.
, vol.31
, Issue.SUPPL.
, pp. 32-43
-
-
Garman, R.H.1
-
12
-
-
53849119826
-
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)
-
White, J. T., Martell, L. A., Van Tuyl, A., Boyer, R., Warness, L., Taniguchi, G. T., and Foehr, E. (2008) Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase) AAPS J. 10, 363-72
-
(2008)
AAPS J.
, vol.10
, pp. 363-372
-
-
White, J.T.1
Martell, L.A.2
Van Tuyl, A.3
Boyer, R.4
Warness, L.5
Taniguchi, G.T.6
Foehr, E.7
-
13
-
-
0028568013
-
Enzyme replacement in a canine model of Hurler syndrome
-
Shull, R. M., Kakkis, E. D., McEntee, M. F., Kania, S. A., Jonas, A. J., and Neufeld, E. F. (1994) Enzyme replacement in a canine model of Hurler syndrome Proc. Natl. Acad. Sci. U. S. A. 91, 12937-41
-
(1994)
Proc. Natl. Acad. Sci. U. S. A.
, vol.91
, pp. 12937-12941
-
-
Shull, R.M.1
Kakkis, E.D.2
McEntee, M.F.3
Kania, S.A.4
Jonas, A.J.5
Neufeld, E.F.6
-
14
-
-
33845930317
-
Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates
-
Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J., Jiang, W., and Wroblewski, V. J. (2007) Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates Drug Metab. Dispos. 35, 86-94
-
(2007)
Drug Metab. Dispos.
, vol.35
, pp. 86-94
-
-
Datta-Mannan, A.1
Witcher, D.R.2
Tang, Y.3
Watkins, J.4
Jiang, W.5
Wroblewski, V.J.6
-
15
-
-
67349241946
-
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
-
Ponce, R., Abad, L., Amaravadi, L., Gelzleichter, T., Gore, E., Green, J., Gupta, S., Herzyk, D., Hurst, C., Ivens, I. A., Kawabata, T., Maier, C., Mounho, B., Rup, B., Shankar, G., Smith, H., Thomas, P., and Wierda, D. (2009) Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies Regul. Toxicol. Pharmacol. 54, 164-82
-
(2009)
Regul. Toxicol. Pharmacol.
, vol.54
, pp. 164-182
-
-
Ponce, R.1
Abad, L.2
Amaravadi, L.3
Gelzleichter, T.4
Gore, E.5
Green, J.6
Gupta, S.7
Herzyk, D.8
Hurst, C.9
Ivens, I.A.10
Kawabata, T.11
Maier, C.12
Mounho, B.13
Rup, B.14
Shankar, G.15
Smith, H.16
Thomas, P.17
Wierda, D.18
-
16
-
-
79952073057
-
Safety evaluation of biological drugs: What are toxicology studies in primates telling us?
-
Baldrick, P. (2011) Safety evaluation of biological drugs: what are toxicology studies in primates telling us? Regul. Toxicol. Pharmacol. 59, 227-36
-
(2011)
Regul. Toxicol. Pharmacol.
, vol.59
, pp. 227-236
-
-
Baldrick, P.1
-
17
-
-
30744440090
-
Development and regulation of monoclonal antibody products: Challenges and opportunities
-
Weinberg, W. C., Frazier-Jessen, M. R., Wu, W. J., Weir, A., Hartsough, M., Keegan, P., and Fuchs, C. (2005) Development and regulation of monoclonal antibody products: challenges and opportunities Cancer Metastasis Rev. 24, 569-84
-
(2005)
Cancer Metastasis Rev.
, vol.24
, pp. 569-584
-
-
Weinberg, W.C.1
Frazier-Jessen, M.R.2
Wu, W.J.3
Weir, A.4
Hartsough, M.5
Keegan, P.6
Fuchs, C.7
-
18
-
-
84857372735
-
The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates
-
Chapman, K. L., Andrews, L., Bajramovic, J. J., Baldrick, P., Black, L. E., Bowman, C. J., Buckley, L. A., Coney, L. A., Couch, J., Maggie-Dempster, A., deHaan, L., Jones, K., Pullen, N., deBoer, A. S., Sims, J., and Ian-Ragan, C. (2012) The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates Regul. Toxicol. Pharmacol. 62, 347-54
-
(2012)
Regul. Toxicol. Pharmacol.
, vol.62
, pp. 347-354
-
-
Chapman, K.L.1
Andrews, L.2
Bajramovic, J.J.3
Baldrick, P.4
Black, L.E.5
Bowman, C.J.6
Buckley, L.A.7
Coney, L.A.8
Couch, J.9
Maggie-Dempster, A.10
Dehaan, L.11
Jones, K.12
Pullen, N.13
Deboer, A.S.14
Sims, J.15
Ian-Ragan, C.16
-
19
-
-
84866457004
-
Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor
-
Boado, R. J., Hui, E. K., Lu, J. Z., and Pardridge, W. M. (2012) Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor Drug Metab. Dispos. 40, 2021-2025
-
(2012)
Drug Metab. Dispos.
, vol.40
, pp. 2021-2025
-
-
Boado, R.J.1
Hui, E.K.2
Lu, J.Z.3
Pardridge, W.M.4
-
20
-
-
59449083175
-
Long-term efficacy and safety of Laronidase in the treatment of Mucopolysaccharidosis i
-
Clarke, L. A., Wraith, J. E., Beck, M., Kolodny, E. H., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Sidman, M., Kakkis, E. D., and Cox, G. F. (2009) Long-term efficacy and safety of Laronidase in the treatment of Mucopolysaccharidosis I Pediatrics 123, 229-240
-
(2009)
Pediatrics
, vol.123
, pp. 229-240
-
-
Clarke, L.A.1
Wraith, J.E.2
Beck, M.3
Kolodny, E.H.4
Pastores, G.M.5
Muenzer, J.6
Rapoport, D.M.7
Berger, K.I.8
Sidman, M.9
Kakkis, E.D.10
Cox, G.F.11
-
21
-
-
84862653625
-
A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in Parkinsonian monkeys
-
Ohshima-Hosoyama, S., Simmons, H. A., Goecks, N., Joers, V., Swanson, C. R., Bondarenko, V., Velotta, R., Brunner, K., Wood, L. D., Hruban, R. H., and Emborg, M. E. (2012) A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in Parkinsonian monkeys PLoS ONE 7, e39036
-
(2012)
PLoS ONE
, vol.7
, pp. 39036
-
-
Ohshima-Hosoyama, S.1
Simmons, H.A.2
Goecks, N.3
Joers, V.4
Swanson, C.R.5
Bondarenko, V.6
Velotta, R.7
Brunner, K.8
Wood, L.D.9
Hruban, R.H.10
Emborg, M.E.11
-
22
-
-
0035020633
-
Pancreatic intraepithelial neoplasia
-
Hruban, R. H., Adsay, N. C., Albores-Sasvedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Kloppel, G., Longnecker, D. S., Luttges, J., and Offerhaus, G. J. (2001) Pancreatic intraepithelial neoplasia Am. J. Surg. Pathol. 25, 579-86
-
(2001)
Am. J. Surg. Pathol.
, vol.25
, pp. 579-586
-
-
Hruban, R.H.1
Adsay, N.C.2
Albores-Sasvedra, J.3
Compton, C.4
Garrett, E.S.5
Goodman, S.N.6
Kern, S.E.7
Klimstra, D.S.8
Kloppel, G.9
Longnecker, D.S.10
Luttges, J.11
Offerhaus, G.J.12
-
23
-
-
79959444718
-
Chronic dosing of mice with a transferrin receptor monoclonal antibody-GDNF fusion protein
-
Zhou, Q. H., Boado, R. J., Lu, J. Z., Hui, E. K., and Pardridge, W. M. (2011) Chronic dosing of mice with a transferrin receptor monoclonal antibody-GDNF fusion protein Drug Metab. Dispos. 39, 1149-54
-
(2011)
Drug Metab. Dispos.
, vol.39
, pp. 1149-1154
-
-
Zhou, Q.H.1
Boado, R.J.2
Lu, J.Z.3
Hui, E.K.4
Pardridge, W.M.5
|